News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
755,020 Results
Type
Article (47233)
Company Profile (353)
Press Release (707419)
Multimedia
Podcasts (152)
Webinars (21)
Section
Business (209275)
Career Advice (2053)
Deals (36254)
Drug Delivery (149)
Drug Development (85078)
Employer Resources (176)
FDA (17173)
Job Trends (15275)
News (355869)
Policy (33631)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2768)
Academic (1)
Accelerated approval (55)
Adcomms (37)
Allergies (182)
Alliances (51142)
ALS (226)
Alzheimer's disease (1894)
Antibody-drug conjugate (ADC) (524)
Approvals (17538)
Artificial intelligence (729)
Autoimmune disease (335)
Automation (61)
Bankruptcy (369)
Best Places to Work (11872)
BIOSECURE Act (23)
Biosimilars (234)
Biotechnology (235)
Bladder cancer (209)
Brain cancer (82)
Breast cancer (824)
Cancer (6376)
Cardiovascular disease (526)
Career advice (1748)
Career pathing (44)
CAR-T (379)
CDC (61)
Celiac Disease (3)
Cell therapy (1041)
Cervical cancer (52)
Clinical research (73867)
Collaboration (2259)
Company closure (7)
Compensation (1479)
Complete response letters (98)
COVID-19 (2854)
CRISPR (121)
C-suite (1223)
Cystic fibrosis (164)
Data (8472)
Decentralized trials (3)
Denatured (38)
Depression (182)
Dermatology (96)
Diabetes (634)
Diagnostics (7137)
Digital health (59)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (357)
Drug pricing (219)
Drug shortages (34)
Duchenne muscular dystrophy (314)
Earnings (93299)
Editorial (73)
Employer branding (21)
Employer resources (155)
Events (123845)
Executive appointments (1136)
FDA (21102)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1851)
Gene editing (261)
Generative AI (62)
Gene therapy (839)
GLP-1 (1163)
Government (4894)
Grass and pollen (6)
Guidances (416)
Healthcare (19700)
HIV (89)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (106)
Immunology and inflammation (328)
Immuno-oncology (109)
Indications (201)
Infectious disease (3220)
Inflammatory bowel disease (230)
Inflation Reduction Act (14)
Influenza (137)
Intellectual property (306)
Interviews (322)
IPO (16948)
IRA (52)
Job creations (3716)
Job search strategy (1446)
JPM (69)
Kidney cancer (22)
Labor market (106)
Layoffs (618)
Leadership (43)
Legal (8074)
Liver cancer (107)
Longevity (35)
Lung cancer (849)
Lymphoma (455)
Machine learning (63)
Management (60)
Manufacturing (1130)
MASH (217)
Medical device (14302)
Medtech (14443)
Mergers & acquisitions (20578)
Metabolic disorders (1667)
mRNA (246)
Multiple sclerosis (197)
NASH (19)
Neurodegenerative disease (482)
Neuropsychiatric disorders (116)
Neuroscience (3546)
Neurotech (1)
NextGen: Class of 2026 (6761)
Non-profit (4653)
Now hiring (79)
Obesity (788)
Opinion (312)
Ovarian cancer (238)
Pain (275)
Pancreatic cancer (336)
Parkinson's disease (397)
Partnered (34)
Patents (625)
Patient recruitment (723)
Peanut (66)
People (61033)
Pharmaceutical (74)
Pharmacy benefit managers (33)
Phase 1 (23104)
Phase 2 (32483)
Phase 3 (24198)
Pipeline (9446)
Policy (350)
Postmarket research (2737)
Preclinical (9863)
Press Release (69)
Prostate cancer (338)
Psychedelics (67)
Radiopharmaceuticals (361)
Rare diseases (1211)
Real estate (6092)
Recruiting (72)
Regulatory (26432)
Reports (57)
Research institute (2552)
Resumes & cover letters (357)
Rett syndrome (40)
RNA editing (27)
RSV (91)
Schizophrenia (187)
Series A (315)
Series B (228)
Service/supplier (12)
Sickle cell disease (125)
Special edition (31)
Spinal muscular atrophy (179)
Sponsored (49)
Startups (3801)
State (2)
Stomach cancer (21)
Supply chain (133)
Tariffs (92)
The Weekly (111)
Vaccines (1184)
Venture capital (120)
Weight loss (522)
Women's health (133)
Worklife (21)
Date
Today (133)
Last 7 days (805)
Last 30 days (3539)
Last 365 days (31436)
2026 (14769)
2025 (31345)
2024 (36409)
2023 (41149)
2022 (52435)
2021 (56953)
2020 (55224)
2019 (47783)
2018 (36072)
2017 (33184)
2016 (32632)
2015 (38662)
2014 (32336)
2013 (27383)
2012 (29513)
2011 (30202)
2010 (28405)
Location
Africa (776)
Alabama (93)
Alaska (7)
Arizona (362)
Arkansas (15)
Asia (41509)
Australia (6889)
California (13909)
Canada (3888)
China (1494)
Colorado (596)
Connecticut (609)
Delaware (424)
Europe (92297)
Florida (2089)
Georgia (451)
Hawaii (3)
Idaho (64)
Illinois (1126)
India (96)
Indiana (624)
Iowa (24)
Japan (570)
Kansas (139)
Kentucky (51)
Louisiana (46)
Maine (76)
Maryland (1657)
Massachusetts (10077)
Michigan (372)
Minnesota (747)
Mississippi (6)
Missouri (158)
Montana (35)
Nebraska (29)
Nevada (145)
New Hampshire (89)
New Jersey (3640)
New Mexico (34)
New York (3674)
North Carolina (1816)
North Dakota (11)
Northern California (6984)
Ohio (414)
Oklahoma (24)
Oregon (44)
Pennsylvania (2782)
Puerto Rico (29)
Rhode Island (51)
South America (1144)
South Carolina (87)
South Dakota (2)
Southern California (5472)
Tennessee (219)
Texas (2228)
United States (49272)
Utah (411)
Vermont (1)
Virginia (333)
Washington D.C. (84)
Washington State (1108)
West Virginia (4)
Wisconsin (137)
Wyoming (2)
755,020 Results for "intra cellular therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
April 27, 2026
·
3 min read
Press Releases
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
April 27, 2026
·
6 min read
Mergers & acquisitions
Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout
Among Intra-Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.
January 13, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson’s Cell Therapy
May 11, 2026
·
4 min read
Pharm Country
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Intra-Cellular Therapies, Inc. today announced that it will participate in three upcoming investor conferences.
March 6, 2024
·
1 min read
Business
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Intra-Cellular Therapies, Inc. today announced the promotion of Michael Halstead, J.D. to the position of President.
March 19, 2024
·
2 min read
Press Releases
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
April 2, 2025
·
10 min read
Pharm Country
Intra-Cellular Therapies to Participate in Two Upcoming May 2024 Investor Conferences
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will participate in two upcoming investor conferences.
May 8, 2024
·
1 min read
Neuroscience
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening up an additional $1 billion in sales. Still, the stock remains “cheap,” according to Jefferies analysts.
December 3, 2024
·
4 min read
·
Annalee Armstrong
Press Releases
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
May 20, 2026
·
4 min read
1 of 75,502
Next
